Dexamethasone effects on cortisol secretion in Alzheimer's disease: Some clinical and hormonal features in suppressor and nonsuppressor patients

Journal of Endocrinological Investigation

Volumn 23, Issue 3, 2000, Pages 178-186

  Murialdo, G ^a   Barreca, A ^a   Nobili, F ^b   Rollero, A ^a   Timossi, G ^a   Gianelli, M V ^a   Copello, F ^a   Rodriguez, G ^b   Polleri, A ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer's disease; Cortisol; Dehydroepiandrosterone sulphate; Dexamethasone suppression test; Insulin like growth factor binding proteins; Insulin like growth factor I; Pituitary adrenal axis

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; HYDROCORTISONE; PRASTERONE SULFATE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; ALZHEIMER DISEASE; ANTHROPOMETRIC PARAMETERS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEXAMETHASONE SUPPRESSION TEST; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE RELEASE; MALE;

EID: 0033997214     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343703     Document Type: Article

References (47)

1. Raskind M.A., Peskind E., Rivard M.-F., Veith R., Barnes R. The dexamethasone suppression test and cortisol circadian rhythm in primary degenerative dementia. Am. J. Psychiatry 1982, 139: 1468-1471.
2. Skare S., Pew B., Dysken M. The dexamethasone suppression test in dementia: a review of the literature. J. Geriatr. Psychiatry Neurol. 1990, 3: 124-138.
3. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N., Kronfold Z., Lohr N., Steinert M., deVigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation and clinical utility. Arch. Gen. Psychiatry 1981, 38: 15-22.
4. Herbert J. Neurosteroids, brain damage, and mental illness. Exp. Gerontol. 1998, 33: 713-727.
5. Davous P., Roudier M., Piketty M.L., Abramowitz C., Lamour Y. Pharmacological modulation of cortisol secretion and dexamethasone suppression in Alzheimer's disease. Biol. Psychiatry 1988, 23: 13-24.
6. Balldin J., Blennow K., Brane G., Gottfries C.G., Karlsson I., Regland B., Wallin A. Relationship between mental impairment and HPA axis activity in dementia disorders. Dementia 1994, 5: 252-256.
7. Magri F., Locatelli M., Balza G., Molla G., Cuzzoni G., Fioravanti M., Solerte S.B., Ferrari E. Changes in endocrine circadian rhythms as markers of physiological and pathological brain aging. Chronobiol. Intern. 1997, 14: 385-396.
8. Wilkinson C.W., Peskind E.R., Raskind M.A. Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. Neuroendocrinology 1997, 65: 79-90.
9. Boscaro M., Paoletta A., Scarpa E., Barzon L., Fusaro P., Fallo F., Sonino N. Age-related changes in glucocorticoid fast feedback inhibition of adrenocorticotropin in man. J. Clin. Endocrinol. Metab. 1998, 83: 1380-1383.
10. Huizenga N.A.T.M., Koper J.W., DeLange P., Pols H.A.P., Stolk R.P., Grobbee D.E., De Jong F.H., Lamberts S.W.J. Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamus-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J. Clin. Endocrinol. Metab. 1998, 83: 47-54.
11. De Kloet E.R., Van der Vies J., DeWied D. The site of suppressive action of dexamethasone on pituitary-adrenal activity. Endocrinology 1974, 94: 61-73.
12. De Kloet E.R., Vreugdenhil E., Oitzl M.S., Joëls M. Brain corticosteroids receptor balance in health and disease. Endocr. Rev. 1998, 19: 269-301.
13. Mc Ewen B.S. Stress and aging hippocampus. Front. Neuroendocrinol2E 1999, 20: 49-70.
14. Svec F., Lopez A. Antiglucocorticoid actions of dehydroepiandrosterone and low concentration in Alzheimer's disease. Lancet 1989, i: 1335-1336.
15. Behl C. Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: implication for the pathogenesis of Alzheimer's disease. Exp. Gerontol. 1998, 33: 689-696.
16. Kalimi M., Shafagoj Y., Loria R., Padgett D., Regelson W. Antiglucocorticoid effects of dehydroepiandrosterone (DHEA). Mol. Cell. Biochem. 1994, 131: 99-104.
17. Baulieu E.E., Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J. Endocrinol. 1996, 150: S221-S239.
18. Kimonides V.G., Khatibi N.H., Svendsen C.N., Sofroniew M.V., Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA 1998, 95: 1852-1857.
19. Guazzo E.P., Kirkpatrick P.J., Goodyer I.M., Shiers H.M., Herbert J. Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J. Clin. Endocrinol. Metab. 1996, 81: 3951-3960.
20. Sunderland T., Merril C.R., Harrington M.G., Lawlor B.A., Molchan S.E., Martinez R., Murphy D.R. Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet 1989, ii: 570.
21. Näsman B., Olsson T., Backstrom T., Eriksson S., Grankvist K., Viitanen M., Bucht G. Serum dehydroepiandrosterone sulfate in Alzheimer's disease and multi-infarct dementia. Biol. Psychiatry 1991, 30: 684-690.
22. Murialdo G., Nobili F., Rollero A., Gianelli M.V., Copello F., Rodriguez G., Polleri A. Hippocampal perfusion and pituitary-adrenal axis in Alzheimer's disease. Neuropsychobiology (in press).
23. Torres-Aleman I. Insulin-like Growth Factors as mediators of functional plasticity in the adult brain. Horm. Metab. Res. 1999, 31: 114-119.
24. Hoffman A.R., Lieberman S.A., Butterfield G., Thompson J., Hintz R.L., Ceda G.P., Marcus R. Functional consequences of somatopause and its treatment. Endocr. Rev. 1997, 7: 73-76.
25. Connor B., Beilharz E.J., Williams C., Synk R., Gluckman P.D., Faull R.L.M., Dragunow M. Insulin-like growth Factor-I (IGF-I) immunoreactivity in the Alzheimer's disease temporal cortex and hippocampus. Mol. Brain Res. 1997, 49: 283-290.
26. Morales A.J., Nolan J.J., Nelson J.C., Yen S.S.C. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 1994, 78: 1360-1367.
27. Pfeilschifter J., Scheidt-Nave C., Leidig-Bruckner G., Woitge H.W., Blum W.F., Wüster C., Haack D., Ziegler R. Relationship between circulating Insulin-like Growth Factor components and sex hormones in a population-based sample of 50-to 80-year-old men and women. J. Clin. Endocrinol. Metab. 1996, 81: 2534-2540.
28. Casson P.R., Santoro N., Elkind-Hirsch K., Carson S.A., Hornsby P.J., Abraham G., Buster J.E. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil. Steril. 1998, 70: 107-110.
29. Jones J., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16: 3-34.
30. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34: 939-944.
31. Folstein M.F., Folstein S.E., McHughes P.R. Mini Mental State: a practical method for grading the cognitive state of patients for clinicians. J. Psychiatry Res. 1975, 12: 189-198.
32. Reisberg B., Ferris S., De Leon M.J., Croock T. The global deterioration scale for assessment of primary degenerative dementia. Am. J. Psychiatry 1982, 139: 1136-1139.
33. Tsagarakis S., Grossman A. The hypothalamus-pituitary-adrenal axis in senescence. Front. Neuroendocrinol. 1999, 20: 70-91.
34. Swanwick G.R.J., Kirby M., Bruce I., Buggy F., Coen R.F., Cakley D., Lawlor B.A. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer's disease: lack of association between longitudinal and cross-sectional findings. Am. J. Psychiatry 1998, 155: 286-289.
35. Sapolsky R.M., Plotsky P.M. Hypercortisolism and its possible neural bases. Biol. Psychiatry 1990, 27: 973.
36. O'Brien J.T., Schweitzer I., Ames D., Tuckwell V., Mastwyk M. Cortisol suppression by dexamethasone in the healthy elderly: effect of age, dexamethasone levels, and cognitive function. Biol. Psychiatry 1994, 36: 389-394.
37. Hatzinger M., Z'Brun A Hemmeter U., Seifritz E., Baumann F., Holsboer-Trachsler E., Heuser I. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer's disease. Neurobiol. Aging 1995, 16: 205-209.
38. Miller A.H., Sastri G., Speranza A.J. jr, Lawlor B.A., Mohs R.C., Ryan T.M., Gabriel S.M., Serby M., Schneider J., Davis K.L. Lack of association between cortisol hypersecretion and non suppression on the DST in patients with Alzheimer's disease. Am. J. Psychiatry 1994, 151: 267-270.
39. Martignoni E., Petraglia F., Costa A., Bono G., Genazzani A.R., Nappi G. Dementia of the Alzheimer type and hypothalamus-pituitary-adrenal axis: changes in cerebrospinal fluid corticotropin releasing factor and plasma cortisol levels. Acta Neurol. Scand. 1990, 81: 452-456.
40. Waltman C., Blackman M.R., Chrousos G.P., Riemann C., Harman S.M. Spontaneous and glucocorticoid-inhibited cortisol secretion in healthy young and old men. J. Clin. Endocrinol. Metab. 1991, 73: 495-502.
41. Bornstein S.R., Chrousos G.P. Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J. Clin. Endocrinol. Metab. 1999, 84: 1729-1736.
42. Rollero A., Murialdo G., Fonzi S., Garrone S., Gianelli M.V., Gazzerro E., Barreca A., Polleri A. Relationship between cognitive function, growth hormone and Insulin-like Growth Factor-I plasma levels in aged subjects. Neuropsychobiology 1998, 38: 73-79.
43. Guan J., Williams C., Gunning M., Mallard C., Gluckman P. The effects of IGF-I treatment after hypoxic-ischemic brain injury in adult rats. J. Cereb. Blood Flow Metab. 1993, 13: 609-616.
44. Doré S., Kar S., Quirion R. Insulin-like Growth Factor-I protects and rescues hippocampal neurons against β-amyloid- and human amylin-induced toxicity. Proc. Natl. Acad. Sci. USA 1997, 94: 4772-4777.
45. Lee P.D.K., Giudice L.C., Conover C.A., Powell D.R. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc. Soc. Exp. Biol. Med. 1997, 216: 319-357.
46. Conover C.A., Clarkson J.T., Bale L.K. Effect of glucocorticoids on Insulin-like Growth Factor regulation of IGF-binding protein expression in fibroblasts. Endocrinology 1995, 136: 1403-1410.
47. Suwanichkul A., Allander S.V., Morris S.L., Powell D.R. Glucocorticoids and insulin regulate expression of the human gene for Insulin-like Growth Factor-Binding protein-1 through proximal promoter element. J. Biol. Chem. 1994, 269: 30835-30841.